MREO
Mereo Biopharma·NASDAQ
--
--(--)
--
--(--)
MREO Profile
Mereo Biopharma Group Plc
A clinical stage biopharmaceutical company focused on rare diseases and oncology
Pharmaceutical
03/10/2015
04/24/2019
NASDAQ Stock Exchange
36
12-31
Depository Receipts (Ordinary Shares)
4th Floor, One Cavendish Place, London, W1G 0QF, United Kingdom
--
Mereo BioPharma Group plc was incorporated under the laws of England and Wales on 10 March 2015. The company is a biopharmaceutical company focused on the development of innovative therapies for rare diseases. It has established a portfolio of late-stage clinical candidates, including setrusumab for osteogenesis imperfecta and alvelestat for α-1 antitrypsin deficiency-related lung disease. The company's strategy involves the selective acquisition and development of rare disease product candidates that have progressed through prior research and development.
